12:00 AM
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PF-00299804: Interim Phase II data

Interim data from an ongoing, open-label, U.S. Phase II trial in 43 evaluable patients, 45 mg/day PF-00299804 produced 3 partial responses and 26 cases of stable disease for >=6 weeks. Seven patients experienced clinical benefit, as defined by partial response plus stable disease, for...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >